Sexual Health Care

• Purpose of This Guideline
• Biomedical Prevention of STIs
• Practical Considerations for Doxy-PEP Implementation
• All Recommendations

• Purpose of This Guideline
• Mpox Prevention
• Mpox Presentation and Diagnosis
• Mpox Treatment
• All Recommendations

• Purpose of This Guidance
• Multifaceted Patient-Centered Sexual Health Care
• Resources for Care Providers

The GOALS framework streamlines sexual history taking to enhance the patient-clinician relationship and elicit information most useful for identifying an appropriate clinical course of action, such as screening, testing, and education.

Go to resource | Download PDF

• Purpose of This Guidance
• Definition, Legality, Eligibility, and Barriers
• Treatment, Medications, and Follow-Up
• Patient Education

• Purpose of This Guideline
• Clinical Manifestations
• Laboratory Testing and Diagnosis
• Treatment
• All Recommendations

• Purpose of This Guideline
• New York State Law and Testing Requirements
• Time to HIV Detection
• HIV Testing With the Standard 3-Step Algorithm
• Diagnosis of HIV-2 Infection
• Appendix: HIV Immunoassays Available in New York State
• All Recommendations

• Purpose of This Guideline
• Rationale
• Who to Test for HCV Infection
• HCV Testing Sequence and Diagnosis
• All Recommendations

• Purpose of This Guideline
• HPV-Associated Cancers
• HPV Prevention
• Cervical and Anal Cancer Screening
• Presentation and Diagnosis of HPV Infection
• HPV Treatment
• Partner Exposure to HIV and HPV
• All Recommendations

• What is U=U?
• Application to Clinical Practice
• Counseling Individuals About U=U
• Counseling Couples About U=U

Please refer to CDC > Sexually Transmitted Infections Treatment Guidelines, 2021

Update: In December 2025, the U.S. Food and Drug Administration approved 2 new oral agents, gepotidacin and zoliflodacin, for treatment of uncomplicated urethral and cervical gonorrhea in patients 12 years or older. For further information, listen to the Conversations with CEI podcast episode “Two New Treatments for Gonorrhea; one is available now!”

• Purpose of This Guideline
• FDA-Approved PrEP Agents
• Who Should Use PrEP
• Comparing PrEP Regimens
• Choosing and Prescribing a PrEP Regimen
• Initiating PrEP
• Ongoing Laboratory Testing
• Managing a Positive HIV Test Result
• Discontinuing PrEP
• Appendix A: Checklists for PrEP Regimen Choice, Assessment and Counseling, Implementation, Initiation, and Follow-Up
• Appendix B: Studies That Support the Use of PrEP in Different Populations
• All Recommendations

• Purpose of This Guideline
• Considerations and Contraindications
• COVID-19
• Haemophilus influenzae Type B (Hib)
• Hepatitis A Virus (HAV)
• Hepatitis B Virus (HBV)
• Human Papillomavirus (HPV)
• Influenza
• Measles, Mumps, Rubella (MMR)
• Meningococcal Serotypes A, C, W, and Y (MenACWY)
• Meningococcal Serotype B (MenB)
• Mpox
• Pneumococcal
• Tetanus, Diphtheria, and Pertussis (Tdap) and Tetanus-Diphtheria (Td)
• Varicella
• Zoster
• All Recommendations

• Purpose of This Guideline
• Substance Use Screening and Risk Assessment: Goals and Definitions
• Screening
• Screening Tools
• Risk Assessment
• Patient Engagement and Interventions
• Diagnosis of Substance Use Disorder
• All Recommendations

• Purpose of This Guidance
• New York State Law and Federal Law
• Disclosure, Consent, and Confidentiality
• Good Practice Reminders and Resources

• Viremic -- Cases in HIV Podcast
• Clinical Guidelines Program Approach to Shared Decision-Making
• PrEP Payment Options
• GOALS Framework for Sexual History Taking in Primary Care
• NYSDOH Health Equity Competencies for Health Care Providers
• Selected Links: Resources for Clinicians
• Selected Links: Resources for Consumers